PMID- 21166862
OWN - NLM
STAT- MEDLINE
DCOM- 20110908
LR  - 20220317
IS  - 1651-2227 (Electronic)
IS  - 0803-5253 (Linking)
VI  - 100
IP  - 7
DP  - 2011 Jul
TI  - Fifteen years of treatment with intravenous immunoglobulin in central nervous 
      system Langerhans cell histiocytosis.
PG  - e36-9
LID - 10.1111/j.1651-2227.2010.02125.x [doi]
AB  - AIM: There is currently no well-accepted therapy for central nervous 
      system Langerhans cell histiocytosis (CNS-LCH), a neuroinflammatory disease 
      clinically characterized by often progressive, neurological symptoms including 
      ataxia, dysarthria, dysphagia, hypertonicity, intellectual impairment and 
      behavioural abnormalities. We applied immunomodulative/anti-inflammatory 
      treatment on a patient with progressive CNS-LCH disease. METHOD: Intravenous 
      immunoglobulin (IVIG) was administered monthly for 15 years to a patient with 
      severe, image-verified neurodegenerative CNS-LCH. RESULTS: During the IVIG 
      treatment, the neurological deterioration initially appeared to be haltered, but 
      over time there was still some deterioration. CONCLUSIONS: IVIG may be beneficial 
      in partly haltering CNS-LCH neurodegeneration, but further studies are needed.
CI  - (c) 2011 The Author(s)/Acta Paediatrica (c) 2011 Foundation Acta Paediatrica.
FAU - Gavhed, Desiree
AU  - Gavhed D
AD  - Childhood Cancer Research Unit, Department of Women's and Children's Health, 
      Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
FAU - Laurencikas, Evaldas
AU  - Laurencikas E
FAU - Akefeldt, Selma O
AU  - Akefeldt SO
FAU - Henter, Jan-Inge
AU  - Henter JI
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110111
PL  - Norway
TA  - Acta Paediatr
JT  - Acta paediatrica (Oslo, Norway : 1992)
JID - 9205968
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Adolescent
MH  - Central Nervous System Diseases/*drug therapy
MH  - Child
MH  - Child, Preschool
MH  - Disease Progression
MH  - Follow-Up Studies
MH  - Histiocytosis, Langerhans-Cell/*drug therapy
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors/*therapeutic use
MH  - Infant
MH  - Male
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2010/12/21 06:00
MHDA- 2011/09/09 06:00
CRDT- 2010/12/21 06:00
PHST- 2010/12/21 06:00 [entrez]
PHST- 2010/12/21 06:00 [pubmed]
PHST- 2011/09/09 06:00 [medline]
AID - 10.1111/j.1651-2227.2010.02125.x [doi]
PST - ppublish
SO  - Acta Paediatr. 2011 Jul;100(7):e36-9. doi: 10.1111/j.1651-2227.2010.02125.x. Epub 
      2011 Jan 11.